경구 고형 제제 수탁제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global oral solid dosage contract manufacturing market report size is expected to reach USD 30.37 Billion in 2034 from USD 13.08 Billion in 2025, growing at a CAGR of 9.81% during 2026-2034.The oral solid dosage (OSD) contract manufacturing market has grown significantly as pharmaceutical companies outsource production to specialized contract development and manufacturing organizations (CDMOs). Tablets and capsules remain the most common drug delivery forms, driving sustained demand. Outsourcing enables cost optimization, scalability, and compliance with global regulatory standards.

Growth drivers include patent expirations leading to generic drug production, increasing small-molecule pipelines, and the need for flexible manufacturing capacity. Technological advancements in high-potency APIs, continuous manufacturing, and quality control systems enhance efficiency. Pharmaceutical firms increasingly rely on CDMOs for formulation development and commercial-scale production.

Future prospects are robust, supported by expanding generic and specialty drug markets. Emerging economies offer cost-competitive manufacturing hubs. Investment in automation, digital quality management, and regulatory compliance will strengthen competitiveness. However, supply chain disruptions and stringent regulatory scrutiny may impact operational dynamics.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Tablets
• Capsules
• Powders
• Granules
• Others

By Mechanism

• Immediate Release
• Delayed Release
• Controlled Release

By End Use

• Large Size Companies
• Medium & Small Size Companies
• Others

COMPANIES PROFILED

• Aenova Group, Boehringer Ingelheim International GmbH, Catalent Inc., Corden Pharma International, Jubilant Pharmova Limited, Lonza, NextPharma GmbH, Piramal Pharma Solutions, Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Capsules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Granules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY MECHANISM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism
• 5.2. Immediate Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Delayed Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Controlled Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Large Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Medium & Small Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Mechanism
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Mechanism
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Mechanism
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Mechanism
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Mechanism
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Aenova Group
  • 9.2.2 Boehringer Ingelheim International GmbH
  • 9.2.3 Catalent Inc
  • 9.2.4 Corden Pharma International
  • 9.2.5 Jubilant Pharmova Limited
  • 9.2.6 Lonza
  • 9.2.7 NextPharma GmbH
  • 9.2.8 Piramal Pharma Solutions
  • 9.2.9 Recipharm AB
  • 9.2.10 Siegfried Holding AG
  • 9.2.11 Thermo Fisher Scientific